Vaccitech induces T cells and antibodies to treat and prevent disease

Learn More

life at vaccitech

Our Mission

Image: NIAID

Treating and Preventing Disease

We discover and develop immunotherapeutics products and vaccines for the treatment and prevention of infectious diseases and cancer

Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the most prestigious vaccine research centres in the world.

Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments

“The first quarter of 2021 was transformational for Vaccitech as we closed a Series B financing round and initiated patient dosing in our two lead therapeutic programs, HBV and HPV,” said Bill Enright, CEO of Vaccitech.

Vaccitech presentation at the Jefferies Virtual Healthcare Conference

Vaccitech today announced that the Company’s Chief Executive Officer, Bill Enright, will be presenting at the Jefferies Virtual Healthcare Conference on Thursday, June 3 at 11:00 AM EDT.

Vaccitech Announces Closing of $110.5 Million Initial Public Offering

Vaccitech today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS.

OUR APPROACH

Teaching the immune system to confront deadly infections

Traditional vaccine technology creates a pronounced antibody response to the infectious agent. Vaccitech’s platform is also able to induce potent and durable T cell responses from the cellular arm of the immune system.